N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy

• US 7,951,821 B2
• Filed: 03/01/2007
• Issued: 05/31/2011
• Est. Priority Date: 07/29/2002
• Status: Expired due to Fees

• Current Assignee: Sanofi-Aventis (Sanofi )
• Original Assignee: Sanofi-Aventis (Sanofi )
• Inventors: Dargazanli, Gihad, Roger, Pierre, Marabout, Benoit, Estenne-Bouhtou, Genevieve, Sevrin, Mireille
• Primary Examiner(s): Chang; Celia
• Application Number:
  US11/680,782
• Publication Number:
  US 20070155789A1
• Time in Patent Office: 1,552 Days
• Field of Search: 514/331, 514/235.5, 514/317, 544/126, 546/186, 546/207, 546/234, 546/247
• US Class Current: 514/317
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/32 Alcohol-abuse
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 211/26 with hydrocarbon radicals, substituted by nitrogen atoms

Abstract

This invention discloses and claims a compound of general formula (I)

in which R₁ represents either a hydrogen atom, or an optionally substituted alkyl group, or a cycloalkylalkyl group, or an optionally substituted phenylalkyl group, or an alkenyl group, X represents a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl, alkyl and alkoxy groups, R₂ represents one or more substituents chosen from halogen atoms, optionally substituted alkoxy and optionally substituted amino. The compounds of this invention exhibit therapeutic utility.

Claims

1. A method of treating a disease selected from the group consisting of dementia, psychoses schizophrenia, acute or chronic extrapyramidal symptoms induced by neuroleptics, anxiety, panic attack, phobia, obsessive-compulsive disorder, depression, disorder due to alcohol abuse or withdrawal from alcohol, migraine, painful muscular contractures in rheumatology or acute spinal pathology, rebellious algia, Parkinson'"'"'s disease, epilepsy, and sleep apnea in a patient comprising administering to said patient a therapeutically effective amount of a compound, in the form of a pure optical isomer (1S,2S) or in the form of a threo diastereoisomer, optionally in combination with a pharmaceutical excipient, wherein said compound is corresponding to general formula (1):

2. The method as set forth in claim 1, wherein said compound is a glyt1 transporter inhibitor.

3. The method as set forth in claim 1, wherein said compound has the configuration (1S,2S), with R₂ representing one or more halogen atoms.

4. The method as set forth in claim 3, wherein said compound is a glyt1 transporter inhibitor.

5. The method as set forth in claim 4, wherein said disease is dementia.

6. The method as set forth in claim 4, wherein said disease is psychoses.

7. The method as set forth in claim 4, wherein said disease is schizophrenia.

8. The method as set forth in claim 7, wherein said schizophrenia is either deficient form or productive form.

9. The method as set forth in claim 4, wherein said disease is acute or chronic extrapyramidal symptoms induced by neuroleptics.

10. The method as set forth in claim 4, wherein said disease is anxiety.

11. The method as set forth in claim 4, wherein said disease is panic attack.

12. The method as set forth in claim 4, wherein said disease is phobia.

13. The method as set forth in claim 4, wherein said disease is obsessive-compulsive disorder.

14. The method as set forth in claim 4, wherein said disease is depression.

15. The method as set forth in claim 14, wherein said depression is psychotic depression.

16. The method as set forth in claim 4, wherein said disease is due to alcohol abuse or withdrawal from alcohol, and migraine.